Trial Profile
A Translational Companion Protocol to GOG229O: A Randomized Phase II Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Trametinib (Primary) ; Uprosertib (Primary)
- Indications Adenocarcinoma; Endometrial cancer
- Focus Biomarker; Pharmacodynamics
- 24 Jan 2020 Status changed from active, no longer recruiting to completed.
- 06 Jan 2020 Planned End Date changed from 31 Aug 2019 to 30 Jan 2020.
- 06 Jan 2020 Planned primary completion date changed from 31 Aug 2019 to 30 Jan 2020.